Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
467 Leser
Artikel bewerten:
(2)

Nutranomics Inc.: NutraNomics Announces Record Topline Growth for New "The Plant" Acquisition During Four Months Ended April 30

Finanznachrichten News

DESERT SPRINGS, CA / ACCESSWIRE / June 21, 2022 / NutraNomics, Inc. (OTC PINK:NNRX) ("NutraNomics" or the "Company"), an emerging leader in organic plant-based nutritional science and innovation, is pleased to announce that its recent acquisition, DHS Development, Inc. (dba "The Plant"), a NutraNomics Company, produced a record-breaking year-to-date year-over-year revenue increase of 217% for the four months ended April 30, 2022.

The Plant and NutraNomics executed an acquisition LOI in January 2022, which included provisions for operational and financial support that fueled an immediate upsurge in growth, according to Company officials.

In addition to consistent Type 7 concentrate sales in Q1 2022, the Company added auxiliary contract packaging services including vape cart filling, pre-roll packaging, and concentrate packaging. Through April of this year, the organization has increased its headcount by 7x to over 70 employees from just 10 employees one year ago.

"The goal for this endeavor was to offer our clients a one-stop shop for product manufacturing, packaging, and delivery of retail-ready products under one roof," says Mattie Cooper, the appointed President of The Plant and its affiliates.

Note, the Company plans to release more information about Mattie Cooper and her important role in the near future.

"The acquisition of The Plant and its affiliates has resulted in a significant jump in production," says CEO Jonathan Bishop, CEO of NutraNomics. "As such, NutraNomics is well positioned for outstanding momentum going into the summer season. We have worked hard on day-to-day operations with a keen focus on future growth in the months and years ahead. I couldn't be more encouraged.

About NutraNomics

At NutraNomics, Inc. (OTC: NNRX), we are committed to excellence in organic plant-based nutritional science and innovation. That was our stance when we began in 1996, and it is still our stance today.

NutraNomics Website: https://www.nutranomics.com

NutraNomics Twitter: https://www.twitter.com/nutranomicsinc

Forward Looking Statements
Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update the information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.

Press Contact:
Geoff Bazegian, IR@nutranomics.com

Public Relations
EDM Media, LLC
https://edm.media

SOURCE: NutraNomics, Inc.



View source version on accesswire.com:
https://www.accesswire.com/705868/NutraNomics-Announces-Record-Topline-Growth-for-New-The-Plant-Acquisition-During-Four-Months-Ended-April-30

© 2022 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.